AGN — Algernon Pharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00
- CA$2.81m
- CA$2.74m
2019 August 31st | 2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.208 | 6.12 | 2.41 | 1.41 | 0.125 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.045 | 1.23 | 2.29 | 0.666 | 0.096 |
Prepaid Expenses | |||||
Total Current Assets | 0.279 | 7.74 | 4.91 | 2.83 | 0.34 |
Net Property, Plant And Equipment | 0 | — | — | — | — |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 5.34 | 12.8 | 10.1 | 8.14 | 4.19 |
Payable / Accrued | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 0.365 | 0.607 | 1.02 | 2.52 | 2.72 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 0.365 | 0.607 | 1.02 | 2.52 | 2.72 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 4.97 | 12.2 | 9.12 | 5.62 | 1.47 |
Total Liabilities & Shareholders' Equity | 5.34 | 12.8 | 10.1 | 8.14 | 4.19 |
Total Common Shares Outstanding |